Distinguishing Clinical Heart Failure from Asymptomatic Cardiac Dysfunction

Definition and Core Diagnostic Components

Clinical heart failure is diagnosed only when both patient‑reported symptoms and objective cardiac abnormalities are present; the term “heart failure physiology” (or cardiac dysfunction) refers to objective abnormalities without symptoms. 1
The European Society of Cardiology and the American College of Cardiology require three concurrent elements for a clinical heart‑failure diagnosis:

The severity of cardiac dysfunction does not reliably predict symptom burden; patients with markedly reduced ejection fraction may be completely asymptomatic, whereas those with preserved ejection fraction can experience severe functional limitation. [2][3]
Factors that modulate symptoms independent of ejection fraction include:

Target population: Adults at high risk for heart failure (e.g., hypertension, coronary artery disease, diabetes).
Initial screening: Resting electrocardiogram (ECG) and measurement of natriuretic peptides. A normal ECG provides >90 % negative predictive value for excluding left‑ventricular systolic dysfunction; low‑normal peptide levels make occult cardiac dysfunction unlikely. [4][5]
Confirmatory testing: If screening suggests abnormality, transthoracic echocardiography is mandatory to document structural or functional cardiac abnormalities. 4

Stage B (asymptomatic structural heart disease / heart‑failure physiology): Initiation of ACE‑inhibitor or ARB therapy plus beta‑blockers is recommended to prevent progression to symptomatic heart failure. 1
Stage C (symptomatic clinical heart failure): Comprehensive neurohormonal blockade—ACE‑inhibitor/ARB, beta‑blocker, and mineralocorticoid‑receptor antagonist—is indicated, as this combination reduces mortality in patients with reduced ejection fraction. 1

Do not diagnose heart failure solely on imaging (e.g., a reduced ejection fraction) without documented symptoms; such cases should be coded as “asymptomatic left‑ventricular dysfunction” or the specific structural abnormality. 2
Do not expect immediate symptom relief after correcting the underlying cardiac dysfunction; hemodynamic improvements may require weeks to months before translating into clinical benefit because of peripheral vascular and muscular adaptations. 3
Always identify and document the underlying etiology (ischemic, hypertensive, valvular, etc.) because etiology‑specific therapies are essential for optimal management. [4][1]

The European Society of Cardiology defines heart failure as a clinical syndrome characterized by typical symptoms and signs caused by a structural and/or functional cardiac abnormality, resulting in reduced cardiac output and/or elevated intracardiac pressures at rest or during stress, with symptoms including breathlessness, ankle swelling, and fatigue, and signs including elevated jugular venous pressure, pulmonary crackles, and peripheral edema 6, 7, 8
The European Society of Cardiology emphasizes that demonstration of an underlying cardiac cause is central to the diagnosis, usually a myocardial abnormality causing systolic and/or diastolic ventricular dysfunction 6, 7, 8
Symptoms typical of heart failure include breathlessness at rest or on exercise, fatigue, tiredness, and ankle swelling, while signs include tachycardia, tachypnea, pulmonary rales, pleural effusion, raised jugular venous pressure, peripheral edema, and hepatomegaly 9
Objective evidence of structural or functional cardiac abnormality at rest includes cardiomegaly, third heart sound, cardiac murmurs, abnormality on echocardiogram, and raised natriuretic peptide concentration 9

The European Society of Cardiology and the American Heart Association classify heart failure based on left ventricular ejection fraction (LVEF), with categories including HFrEF (LVEF ≤40%), HFmrEF (LVEF 41-49%), and HFpEF (LVEF ≥50%) 6, 7, 8
The New York Heart Association (NYHA) functional classification is used by both societies, with classes including Class I (no limitation), Class II (slight limitation), Class III (marked limitation), and Class IV (unable to carry out any physical activity without discomfort) 10

A normal ECG makes heart failure, especially due to LV systolic dysfunction, unlikely, while low-normal natriuretic peptide concentrations in an untreated patient make heart failure unlikely 10
Asymptomatic structural or functional cardiac abnormalities are recognized as precursors of heart failure, and starting treatment at the precursor stage may reduce mortality 6, 7, 8